Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 3/20 | 0.56 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.48 |
| ▸ | ALPL | P05186 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819723 | 0.88 | XDH (0.53) | PIP4K2APIP4K2BXDHSLC22A12PIK3CB | |
| SCHEMBL4196597 | 0.87 | CYP1A2 (0.60) | PIP4K2APIP4K2BXDHSLC22A12PTGS1 | |
| SCHEMBL4200935 | 0.85 | PIP4K2A (0.58) | PIP4K2APIP4K2BXDHSLC22A12PTGS1 | |
| SCHEMBL4187496 | 0.84 | FYN (0.69) | PIP4K2APIP4K2BFYNTGFBR1ACVR1 | |
| SCHEMBL4191762 | 0.83 | PIP4K2A (0.59) | PIP4K2APIP4K2BPIK3CBCYP1A2CYP3A4 | |
| SCHEMBL4194464 | 0.82 | PIP4K2A (0.55) | PIP4K2APIP4K2BSLC22A12PIK3CBCYP1A2 | |
| SCHEMBL4198997 | 0.81 | BRAF (0.72) | PIP4K2APIP4K2BXDHSLC22A12FYN | |
| SCHEMBL4196450 | 0.81 | PIP4K2A (0.58) | PIP4K2APIP4K2BXDHSLC22A12PTGS1 | |
| SCHEMBL2821275 | 0.80 | XDH (0.56) | XDHSLC22A12PIK3CBFYNBRAF | |
| SCHEMBL4143146 | 0.80 | XDH (0.62) | XDHSLC22A12FYNBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-8288421-B2 | neoplastic disease, autoimmune disease, transplantation related pathology and/or degenerative disease; selectively inducing apoptosis in cancer cells | BASILEA PHARMACEUTICA AG (CH) | 2012-10-16 | — | — | US | disclosed |
| EP-1789044-B1 | PHENYLAMINOPYRIDINES AND PHENYLAMINOPYRAZINES | BASILEA PHARMACEUTICA AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20080221171-A1 | Phenylaminopyridines | BASILEA PHARMACEUTICA AG (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1789044-A1 | PHENYLAMINOPYRIDINES | Basilea Pharmaceutica AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006027348-A1 | PHENYLAMINOPYRIDINES | BASILEA PHARMACEUTICA AG (CH) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221171-A1 | Phenylaminopyridines | P2RY11, BCL9, TPMT | PIP4K2A 1960/4885PIP4K2B 2048/4885XDH 600/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | PIP4K2A 748/4885PIP4K2B 633/4885XDH 1630/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | PIP4K2A 748/4885PIP4K2B 633/4885XDH 1630/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | PIP4K2A 748/4885PIP4K2B 633/4885XDH 1630/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | PIP4K2A 1599/4885PIP4K2B 1968/4885XDH 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.